Digestive Diseases and Sciences

, Volume 46, Issue 3, pp 540–544

Role of Fibrates and HMG-CoA Reductase Inhibitors in Gallstone Formation

  • Francois-Xavier Caroli-Bosc
  • Philippe Le Gall
  • Pascal Pugliese
  • Benoit Delabre
  • Corinne Caroli-Bosc
  • Jean-Francois Demarquay
  • Jean-Pierre Delmont
  • Patrick Rampal
  • J.C. Montet
Article

DOI: 10.1023/A:1005643014395

Cite this article as:
Caroli-Bosc, FX., Gall, P.L., Pugliese, P. et al. Dig Dis Sci (2001) 46: 540. doi:10.1023/A:1005643014395

Abstract

Fibrate derivatives and HMG-CoA reductase inhibitors modify homeostasis of cholesterol. The aim of this study was to assess in an unselected population whether these hypolipidemic drugs are risk factors for cholelithiasis or, conversely, are protective agents. Both sexes, all socioeconomic categories, pregnant women, and cholecystectomized subjects were included. Clinical data collection and gallbladder ultrasonography were both carried out in a double-blind fashion. Fibrate derivatives were predominantly fenofibrate, HMG-CoA reductase inhibitors were simvastatin and pravastatin. On univariate analysis, age (>50 years), sex, and use of fibrates were found to be significantly related to the presence of cholelithiasis. Age, sex, and fibrate treatment remained independently correlated with the presence of gallstones on multivariate analysis. With fibrates, the relative risk for lithiasis was 1.7 (P = 0.04). The HMG-CoA reductase inhibitors were not associated with a protective effect on univariate analysis. Of the lipid-lowering drugs, only fibrate derivatives were found to increase the risk of gallstone formation.

gallstonesHMG-CoA reductase inhibitorsfibrates

Copyright information

© Plenum Publishing Corporation 2001

Authors and Affiliations

  • Francois-Xavier Caroli-Bosc
  • Philippe Le Gall
  • Pascal Pugliese
  • Benoit Delabre
  • Corinne Caroli-Bosc
  • Jean-Francois Demarquay
  • Jean-Pierre Delmont
  • Patrick Rampal
  • J.C. Montet

There are no affiliations available